Valneva SE Expected to Post Q3 2024 Earnings of ($0.29) Per Share (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN) – Stock analysts at HC Wainwright increased their Q3 2024 EPS estimates for Valneva in a research report issued on Wednesday, September 25th. HC Wainwright analyst E. White now expects that the company will earn ($0.29) per share for the quarter, up from their previous estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Valneva’s Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.38) EPS.

Valneva Stock Performance

VALN stock opened at $6.21 on Friday. The firm has a market cap of $432.46 million, a price-to-earnings ratio of -15.15 and a beta of 2.19. The firm has a 50-day simple moving average of $7.06 and a two-hundred day simple moving average of $7.57. Valneva has a one year low of $5.70 and a one year high of $14.49. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.15 and a current ratio of 2.63.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.02. The business had revenue of $40.97 million during the quarter, compared to analyst estimates of $46.83 million. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its stake in Valneva SE (NASDAQ:VALN) by 42.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 88,252 shares of the company’s stock after purchasing an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.